Latigo Biotherapeutics, Vivace Therapeutics, and Vori Health each announced the recent successful closing of their respective ...

Nephronophthisis (NPH) is a recessive cystic kidney disease responsible for 10% to 20% of pediatric end-stage renal disease cases. NPHP1 (nephrocystin 1) is the most frequently implicated among over ...

Vivace Therapeutics has closed $35m in a Series D financing round to support the clinical development of its cancer drug ...

California-based Vivace Therapeutics has announced the closing of a $35 million Series D financing. The proceeds will support ...

The pharma giant announced a new partnership with BridGene Biosciences that will use its IMTAC platform for drug discovery.

Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class cancer therapies targeting the Hippo pathway, today announced the closing of a $35 million ...

Single-cell analysis revealed the molecular triggers that drive stem cells to become cancerous, which may help inform ...

This review highlights the critical role of ubiquitination in governing the functionality of cancer stem cells (CSCs), ...

The World Bank’s new mission is to end extreme poverty and boost shared prosperity on a livable planet. The "Poverty, Prosperity, and Planet. Pathways Out of the Polycrisis" report evaluates progress ...

Hippo signalling is a cell signalling pathway that controls organ size. Activation of Hippo results in a series of phosphorylation events that culminate in the phosphorylation and cytoplasmic ...

Janus kinase/signal transduction and transcription activation (JAK/STAT) pathways were originally thought to be intracellular signaling pathways that mediate cytokine signals in mammals. Existing ...

The answer is an unequivocal yes. Generally, it’s best to avoid hippos totally. If a hippo does happen to attack, the odds of living through it depend on whether you can get away or not. Sadly, if a ...